Response to Biologic Therapy in Skin of Colour Participants With Moderate-to-Severe Psoriasis and Atopic Dermatitis: A Systematic Review
Journal of Cutaneous Medicine and Surgery · 2024
DOI: 10.1177/12034754241260023 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cutaneous Medicine and Surgery, 2024. Verfasst von Hibo Rijal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Queen's University School of Medicine, Kingston, ON, Canada. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Psoriasis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
There has been a call to action to enhance representation of non-white individuals in dermatology clinical trials. Investigations in differential response to treatment across populations are limited, particularly in conditions of commonality, impact, distinct presentation, and diagnosis in non-white participants, such as atopic dermatitis and psoriasis. This systematic review summarized and identified if biologic treatment outcomes in moderate-to-severe atopic dermatitis and psoriasis varied in skin of colour (SOC) participants in phase 3 trials. MEDLINE, COCHRANE, and EMBASE databases were used to conduct the search following PROSPERO registration. Following screening of 3209 articles, 11 studies were collected with 1781 SOC participants with a mean age of 40.99 ± 6.3 years (range: 30.6-51.6 years). Male participants accounted for 76.9% (n = 1370/1781) of the sample, and Chinese, Japanese, Taiwanese, and Korean participants accounted for 64.3%, 24.2%, 4.5%, and 3.4% of participants, respectively. Participants with atopic dermatitis were treated with dupilumab (n = 216/388) and participants with psoriasis were treated with adalimumab (n = 313/1393), bimekizumab (n = 62/1393), ixekizumab (n = 13/1393), secukinumab (n = 117/1393), and ustekinumab (n = 289/1393). No significant SOC population-based outcomes were found across treatment groups. However, differences in baseline characteristics or comorbidities were found, suggesting race or ethnic background should be considered when treatment is prescribed in psoriasis or atopic dermatitis. Although no significant SOC participant differential response to treatment were found, large-scale randomized controlled trials investigating comparable treatment outcomes and stratifying results by SOC population in atopic dermatitis and psoriasis are warranted to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Queen's University School of Medicine, Kingston, ON, Canada.
- Faculty of Medicine, Université Laval, Québec City, QC, Canada.
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
- Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
- Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
ORCID-Profile: Hibo Rijal, Naïla Bouadi, Khalad Maliyar, Jorge-Ryan Georgakopoulos
Zitieren
APA
Rijal, H., Bouadi, N., Abduelmula, A., Maliyar, K., Bourkas, A. N., Georgakopoulos, J. R., & Yeung, J. (2024). Response to Biologic Therapy in Skin of Colour Participants With Moderate-to-Severe Psoriasis and Atopic Dermatitis: A Systematic Review. Journal of Cutaneous Medicine and Surgery. https://doi.org/10.1177/12034754241260023
Vancouver
Rijal H, Bouadi N, Abduelmula A, Maliyar K, Bourkas AN, Georgakopoulos JR, et al. Response to Biologic Therapy in Skin of Colour Participants With Moderate-to-Severe Psoriasis and Atopic Dermatitis: A Systematic Review. Journal of Cutaneous Medicine and Surgery. 2024. doi:10.1177/12034754241260023
BibTeX
@article{Rijal2024,
author = {Rijal, Hibo and Bouadi, Naïla and Abduelmula, Abrahim and Maliyar, Khalad and Bourkas, Adrienn N and Georgakopoulos, Jorge-Ryan and Yeung, Jensen},
title = {Response to Biologic Therapy in Skin of Colour Participants With Moderate-to-Severe Psoriasis and Atopic Dermatitis: A Systematic Review},
journal = {Journal of Cutaneous Medicine and Surgery},
year = {2024},
doi = {10.1177/12034754241260023}
}
EUVIMED